Antinuclear Antibody Test Market: Overview
Antinuclear antibodies are a group of autoantibodies produced by an individual’s immune system when it fails to distinguish between self and foreign particles. Antinuclear antibody (ANA) is also known as fluorescent antinuclear antibody (FANA) and antinuclear antibody screen. Antinuclear antibodies attack body’s own cells. Hence, these are called antinuclear, as these target the nucleus of cells. Antinuclear antibodies react with components of the body’s own healthy cells and cause symptoms and signs such as organ & tissue inflammation, muscle & joint pain, and fatigue. Antinuclear antibodies test detects autoantibodies in the blood. An antinuclear antibodies test determines the presence of antinuclear antibodies in the blood. If a test detects antinuclear antibodies in the body of an individual, it could mean that the person has an autoimmune disorder. An antinuclear antibodies test is used to help diagnose autoimmune disorders, including rheumatoid arthritis, scleroderma, Sjogren's syndrome (a rare disease condition that affects the body’s moisture-making glands), and systemic lupus erythematosus (the most common type of lupus, a chronic condition affecting multiple parts of the body including kidneys, blood vessels, brain, and joints).
Antinuclear Antibody Test Market: Key Trends
The global antinuclear antibody test market is projected to grow at a rapid pace during the forecast period. Rise in prevalence of autoimmune disorders such as rheumatoid arthritis and systemic lupus erythematosus and increase in adoption of antinuclear antibodies tests are the major factors anticipated to drive the global market during the forecast period. According to the Lupus Foundation of America, about 5 million people across the globe and an estimated 1.5 million people in the U.S. are suffering from lupus. Based on an estimation, the incidence rate of lupus is 16,000 new cases per year. Lupus affects mostly women of childbearing age. However, children, teenagers, and men develop lupus too. Most of the people suffering from lupus develop the disease between ages 15 and 44. According to the Arthritis Foundation, about 1 in 3 people aged between 18 and 64 have arthritis. The number of adults in the U.S. with doctor-diagnosed arthritis is estimated to rise by 49% to reach 78.4 million (25.9% of all adults) by 2040.
Antinuclear Antibody Test Market: Segmentation
The global antinuclear antibody test market can be segmented based on product, application, technique, and region. In terms of product, the market can be classified into reagents & assay kits, systems, and software & services. The reagents & assay kits segment is projected to account for the largest market share during the forecast period. This is due to high adoption of reagents and assay kits in research and clinic settings. Based on application, the global antinuclear antibody test market can be categorized into systemic lupus erythematosus, rheumatoid arthritis, scleroderma, Sjogren’s syndrome, and others. In terms of technique, the market can be divided into immunofluorescence assay, multiplex assay, and enzyme-linked immunosorbent assay (ELISA). The ELISA segment is anticipated to grow at a rapid pace during the forecast period due to ease of use and moderate level of operator skills required to perform the test.
Antinuclear Antibody Test Market: Regional Analysis
Based on region, the global antinuclear antibody test market can be segmented into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America is projected to lead the global market during the forecast period, followed by Europe. Dominance of the two regions is attributed to high patient awareness, better health care infrastructure, and presence of advanced tests. Asia Pacific is expected to be the fastest growing market during the forecast period due to high prevalence of autoimmune diseases in countries such as India and China.
Antinuclear Antibody Test Market: Competitive Landscape
Key players operating in the global antinuclear antibody test market include Bio-Rad Laboratories, Alere, Inc., Antibodies, Inc., ZEUS Scientific, Erba Diagnostics, Immuno Concepts, Inova Diagnostics, Trinity Biotech plc, and Euroimmun AG.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.